ISSN 1016-5169 | E-ISSN 1308-4488
pdf
Symptomatic Severe Bradycardia during Pazopanib Treatment [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. Ahead of Print: TKDA-03788 | DOI: 10.5543/tkda.2024.03788

Symptomatic Severe Bradycardia during Pazopanib Treatment

Cafer Zorkun, Öykü Alara Eren
Department of Cardiology, Istanbul University, Faculty of Medicine, Istanbul, Türkiye

Pazopanib, a tyrosine kinase inhibitor targeting growth factor receptors, has diverse side effects including bradycardia. We present an extreme case of symptomatic bradycardia (28 bpm) in cardiac angiosarcoma patient on 800 mg/day pazopanib. Reducing to 600 mg/day restored heart rate to 53 bpm, underscoring potential severe bradycardia due to pazopanib, necessitating vigilant heart rate monitoring.

Keywords: Cardiotoxicity, angiosarcoma, pazopanib, permissive cardiotoxicity

How to cite this article


Corresponding Author: Cafer Zorkun
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.